Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747)

Research output: Contribution to journalArticlepeer-review

Standard

Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747). / Pirrie, Sarah; Barton, Darren; Brown, Janet Elizabeth; Billingham, Lucinda; Collins, Stuart I; Daunton, Adam; Birtle, Alison J; Chakraborti, Prabir Ranjan; Ford, Daniel; Hussain, Syed A; Jones, Helen; Pope, Ann; Porfiri, Emilio; Russell, John Martin; Stanley, Andrew; Staffurth, John; McLaren, Duncan; Parker, Chris; Wylie, James.

In: Journal of Clinical Oncology , Vol. 31, No. 18_suppl, 20.06.2013, p. LBA5000.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Pirrie, S., Barton, D., Brown, J. E., Billingham, L., Collins, S. I., Daunton, A., Birtle, A. J., Chakraborti, P. R., Ford, D., Hussain, S. A., Jones, H., Pope, A., Porfiri, E., Russell, J. M., Stanley, A., Staffurth, J., McLaren, D., Parker, C., & Wylie, J. (2013). Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747). Journal of Clinical Oncology , 31(18_suppl), LBA5000. https://doi.org/10.1200/jco.2013.31.18_suppl.lba5000

Vancouver

Author

Pirrie, Sarah ; Barton, Darren ; Brown, Janet Elizabeth ; Billingham, Lucinda ; Collins, Stuart I ; Daunton, Adam ; Birtle, Alison J ; Chakraborti, Prabir Ranjan ; Ford, Daniel ; Hussain, Syed A ; Jones, Helen ; Pope, Ann ; Porfiri, Emilio ; Russell, John Martin ; Stanley, Andrew ; Staffurth, John ; McLaren, Duncan ; Parker, Chris ; Wylie, James. / Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747). In: Journal of Clinical Oncology . 2013 ; Vol. 31, No. 18_suppl. pp. LBA5000.

Bibtex

@article{cd0b30909a654e14ad988ac72d532af5,
title = "Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747)",
abstract = "LBA5000 Background: Bony metastatic CRPC has a poor prognosis and high morbidity. TRAPEZE is a factorial RCT using three agents, D, ZA, and Sr89. All have palliative benefits and are used in bony metastatic CRPC to control bone symptoms and (for D) to prolong survival. ZA was approved on the basis of reducing skeletal related events (SRE). Sr89 was approved to control pain from metastases and to reduce the need for subsequent bone treatments. ZA is commonly combined with D in practice but evidence that the combination is effective is lacking and costs considerable. Sr89 is generally used as a palliative therapy in patients unfit for chemotherapy. Phase II analysis confirmed the safety and feasibility of combining these agents. TRAPEZE aimed to determine clinical and cost-effectiveness scheduling.METHODS: Patients were randomised to receive 6 cycles of D plus prednisolone: alone; with ZA; with a single dose of Sr89 after cycle 6 or both. Primary outcomes were clinical progression-free survival (CPFS: pain progression, SRE or death) and cost-effectiveness. Secondary outcomes were SRE free interval (SREFI); total SREs, and overall survival (OS). The log rank test and Cox regression modelling were used to determine clinical effectiveness.RESULTS: TRAPEZE randomised 757 patients; median age 68.7 yrs; ECOG 0: 40% 1: 52% 2: 8%; prior RT 45%; median PSA 144 (IQR 51, 354). Provisional stratified log rank analysis of CPFS did not reach statistical significance for either agent (Sr89 p=0.11, ZA p=0.45). Cox regression analysis adjusted for all stratification variables showed benefit of Sr89 on CPFS (HR=0.845; 95%CI 0.72, 0.99, p=0.036) and confirmed no effect of ZA (p=0.46). ZA did show a significant effect on SREFI (HR=0.76; 95%CI 0.63, 0.93, p=0.008). There was no effect of either agent on overall survival (Sr89 p=0.74, ZA p=0.91).CONCLUSIONS: Sr89 after six cycles of docetaxel improved CPFS but not OS. ZA did not improve CPFS or OS but did significantly improve median SREFI, mostly post progression, suggesting a role as post chemotherapy maintenance therapy. Further health economic and QoL analyses are pending.CLINICAL TRIAL INFORMATION: 12808747.",
keywords = "Journal Article",
author = "Sarah Pirrie and Darren Barton and Brown, {Janet Elizabeth} and Lucinda Billingham and Collins, {Stuart I} and Adam Daunton and Birtle, {Alison J} and Chakraborti, {Prabir Ranjan} and Daniel Ford and Hussain, {Syed A} and Helen Jones and Ann Pope and Emilio Porfiri and Russell, {John Martin} and Andrew Stanley and John Staffurth and Duncan McLaren and Chris Parker and James Wylie",
year = "2013",
month = jun,
day = "20",
doi = "10.1200/jco.2013.31.18_suppl.lba5000",
language = "English",
volume = "31",
pages = "LBA5000",
journal = "Journal of Clinical Oncology ",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "18_suppl",
note = "2013 ASCO Annual Meeting ; Conference date: 31-05-2013 Through 04-06-2013",

}

RIS

TY - JOUR

T1 - Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747)

AU - Pirrie, Sarah

AU - Barton, Darren

AU - Brown, Janet Elizabeth

AU - Billingham, Lucinda

AU - Collins, Stuart I

AU - Daunton, Adam

AU - Birtle, Alison J

AU - Chakraborti, Prabir Ranjan

AU - Ford, Daniel

AU - Hussain, Syed A

AU - Jones, Helen

AU - Pope, Ann

AU - Porfiri, Emilio

AU - Russell, John Martin

AU - Stanley, Andrew

AU - Staffurth, John

AU - McLaren, Duncan

AU - Parker, Chris

AU - Wylie, James

PY - 2013/6/20

Y1 - 2013/6/20

N2 - LBA5000 Background: Bony metastatic CRPC has a poor prognosis and high morbidity. TRAPEZE is a factorial RCT using three agents, D, ZA, and Sr89. All have palliative benefits and are used in bony metastatic CRPC to control bone symptoms and (for D) to prolong survival. ZA was approved on the basis of reducing skeletal related events (SRE). Sr89 was approved to control pain from metastases and to reduce the need for subsequent bone treatments. ZA is commonly combined with D in practice but evidence that the combination is effective is lacking and costs considerable. Sr89 is generally used as a palliative therapy in patients unfit for chemotherapy. Phase II analysis confirmed the safety and feasibility of combining these agents. TRAPEZE aimed to determine clinical and cost-effectiveness scheduling.METHODS: Patients were randomised to receive 6 cycles of D plus prednisolone: alone; with ZA; with a single dose of Sr89 after cycle 6 or both. Primary outcomes were clinical progression-free survival (CPFS: pain progression, SRE or death) and cost-effectiveness. Secondary outcomes were SRE free interval (SREFI); total SREs, and overall survival (OS). The log rank test and Cox regression modelling were used to determine clinical effectiveness.RESULTS: TRAPEZE randomised 757 patients; median age 68.7 yrs; ECOG 0: 40% 1: 52% 2: 8%; prior RT 45%; median PSA 144 (IQR 51, 354). Provisional stratified log rank analysis of CPFS did not reach statistical significance for either agent (Sr89 p=0.11, ZA p=0.45). Cox regression analysis adjusted for all stratification variables showed benefit of Sr89 on CPFS (HR=0.845; 95%CI 0.72, 0.99, p=0.036) and confirmed no effect of ZA (p=0.46). ZA did show a significant effect on SREFI (HR=0.76; 95%CI 0.63, 0.93, p=0.008). There was no effect of either agent on overall survival (Sr89 p=0.74, ZA p=0.91).CONCLUSIONS: Sr89 after six cycles of docetaxel improved CPFS but not OS. ZA did not improve CPFS or OS but did significantly improve median SREFI, mostly post progression, suggesting a role as post chemotherapy maintenance therapy. Further health economic and QoL analyses are pending.CLINICAL TRIAL INFORMATION: 12808747.

AB - LBA5000 Background: Bony metastatic CRPC has a poor prognosis and high morbidity. TRAPEZE is a factorial RCT using three agents, D, ZA, and Sr89. All have palliative benefits and are used in bony metastatic CRPC to control bone symptoms and (for D) to prolong survival. ZA was approved on the basis of reducing skeletal related events (SRE). Sr89 was approved to control pain from metastases and to reduce the need for subsequent bone treatments. ZA is commonly combined with D in practice but evidence that the combination is effective is lacking and costs considerable. Sr89 is generally used as a palliative therapy in patients unfit for chemotherapy. Phase II analysis confirmed the safety and feasibility of combining these agents. TRAPEZE aimed to determine clinical and cost-effectiveness scheduling.METHODS: Patients were randomised to receive 6 cycles of D plus prednisolone: alone; with ZA; with a single dose of Sr89 after cycle 6 or both. Primary outcomes were clinical progression-free survival (CPFS: pain progression, SRE or death) and cost-effectiveness. Secondary outcomes were SRE free interval (SREFI); total SREs, and overall survival (OS). The log rank test and Cox regression modelling were used to determine clinical effectiveness.RESULTS: TRAPEZE randomised 757 patients; median age 68.7 yrs; ECOG 0: 40% 1: 52% 2: 8%; prior RT 45%; median PSA 144 (IQR 51, 354). Provisional stratified log rank analysis of CPFS did not reach statistical significance for either agent (Sr89 p=0.11, ZA p=0.45). Cox regression analysis adjusted for all stratification variables showed benefit of Sr89 on CPFS (HR=0.845; 95%CI 0.72, 0.99, p=0.036) and confirmed no effect of ZA (p=0.46). ZA did show a significant effect on SREFI (HR=0.76; 95%CI 0.63, 0.93, p=0.008). There was no effect of either agent on overall survival (Sr89 p=0.74, ZA p=0.91).CONCLUSIONS: Sr89 after six cycles of docetaxel improved CPFS but not OS. ZA did not improve CPFS or OS but did significantly improve median SREFI, mostly post progression, suggesting a role as post chemotherapy maintenance therapy. Further health economic and QoL analyses are pending.CLINICAL TRIAL INFORMATION: 12808747.

KW - Journal Article

UR - http://meetinglibrary.asco.org/record/110280/abstract

U2 - 10.1200/jco.2013.31.18_suppl.lba5000

DO - 10.1200/jco.2013.31.18_suppl.lba5000

M3 - Article

C2 - 28136068

VL - 31

SP - LBA5000

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 18_suppl

T2 - 2013 ASCO Annual Meeting

Y2 - 31 May 2013 through 4 June 2013

ER -